PTO/SB/08a/b (07-05) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/552,340 INFORMATION DISCLOSURE Filing Date October 6, 2005 STATEMENT BY APPLICANT First Named Inventor Toshihiro Yamamoto N/A Art Unit (Use as many she ets as necessary) Examiner Name Not Yet Assigned 1 64301(46590) Sheet 1 of Attorney Docket Number

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	
	AA*	US-5,643,911-A			
	AB*	US-5,324,727-A			
	AC*	US-5,089,494-A			

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages		
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T°	
	BA	JP-10-109936-A				1	
	BB	JP-2-129180-A	·			1	
	ВС	JP-62-228067-A					
	BD	WO-01/89517					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	CA	G. Cheng et al., Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5, Gene, 2001, 269(1-2), 131.		
	СВ	S. Shimohama et al., Activation of NADPH Oxidase in Alzheimer's Disease Brains, Biochem. Biophys. Res. Commun. 2000, 273(1), 5.		
	СС	S. DeAtley et al., Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture, Toxicology, 1999 May 3, 134(1): 51-62.		
	CD	T. Münzel et al., Evidence for Enhanced Vascular Superoxide Anion Production in Nitrate Tolerance, J. Clinical Investigation, 1995, 187-194.		
	CE	K. Griendling et al., NAD(P)H Oxidase Role in Cardiovascular Biology and Disease, Circ-Res. 2000, 86, 494-501.		
	CF	U. Bayraktutan et al., Expression of a functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells, Cardiovascular Research, 1998, 38, 256-262.		
	CG	Y. Li et al., Diphenyleneiodonium, an NAD(P)H Oxidase Inhibitor, also Potently Inhibits Mitochondrial Reactive Oxygen Species Production, Biochem. Biophys. Res. Commun. 1998, 253, 295.		
	СН	A. Cayatte et al., S17834, a New Inhibitor of Cell Adhesion and Atherosclerosis that Targets NADPH Oxidase, Arterioscler. Thromb. Vasc. Biol., 2001, 21:1577.		
	CI	M. Geiszt et al., Chronic granulomatous disease: more than the lack of superoxide? J. Leukoc. Biol. 2001, 69, 191.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Susan Hanley/	Date	12/02/2008
Signature		Considered	12/02/2006